Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a ...

San Diego—May 19, 2025–Rady Children’s Institute for Genomic Medicine (RCIGM®) today announced that Alexion, AstraZeneca Rare Disease has signed on as the first Platinum member of the Begin ...

Please provide your email address to receive an email ... Disclosures: Lee reports consulting for Alexion, Amgen/Horizon, AstraZeneca, Bristol Myers Squibb, Catalyst, Dompe, Etyreal, Stoke ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a $753 million hit for abandoning one of the drugs from that ...

Please provide your email address to receive an email when new articles are posted on . In an early study, a gene-editing therapy drastically reduced levels of transthyretin, the protein that ...

Voydeya was developed within Alexion, AstraZeneca Rare Disease, the pharma giant’s rare disease division created from the 2021 acquisition of Alexion Pharmaceuticals for $39 billion. As a ...

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. AstraZeneca on Wednesday ...